Deciphera Pharmaceuticals (NASDAQ:DCPH) Cut to “Market Perform” at Leerink Partnrs

Leerink Partnrs cut shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from an outperform rating to a market perform rating in a research report report published on Monday, Zacks.com reports.

Several other equities research analysts have also recently issued reports on the company. Jefferies Financial Group restated a hold rating and set a $25.60 price objective (down previously from $26.00) on shares of Deciphera Pharmaceuticals in a report on Monday. JMP Securities reiterated a market perform rating on shares of Deciphera Pharmaceuticals in a report on Tuesday. Guggenheim restated a neutral rating on shares of Deciphera Pharmaceuticals in a report on Tuesday. Jonestrading reiterated a hold rating and set a $25.60 price objective on shares of Deciphera Pharmaceuticals in a research note on Monday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a neutral rating in a report on Wednesday, March 20th. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of Hold and an average target price of $24.17.

Deciphera Pharmaceuticals Stock Up 0.4 %

DCPH stock opened at $25.36 on Monday. Deciphera Pharmaceuticals has a 52-week low of $9.90 and a 52-week high of $25.40. The stock’s fifty day simple moving average is $16.18 and its 200-day simple moving average is $14.63. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of -11.07 and a beta of 0.39.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The business had revenue of $48.30 million for the quarter, compared to analysts’ expectations of $45.93 million. During the same quarter last year, the firm earned ($0.60) earnings per share. The business’s revenue was up 32.9% on a year-over-year basis. As a group, analysts anticipate that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DCPH. Quest Partners LLC bought a new position in shares of Deciphera Pharmaceuticals during the fourth quarter worth about $30,000. China Universal Asset Management Co. Ltd. lifted its holdings in Deciphera Pharmaceuticals by 96.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after acquiring an additional 997 shares during the last quarter. AJOVista LLC bought a new position in Deciphera Pharmaceuticals in the fourth quarter worth about $76,000. Exchange Traded Concepts LLC lifted its holdings in Deciphera Pharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company’s stock worth $169,000 after acquiring an additional 2,649 shares during the last quarter. Finally, Diversified Trust Co bought a new position in Deciphera Pharmaceuticals in the fourth quarter worth about $193,000. 70.96% of the stock is owned by hedge funds and other institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.